Clinical study with bleomycin

Sachidananda Shastri,R. Slayton,J. Wolter,C. Perlia,S. Taylor
DOI: https://doi.org/10.1002/1097-0142(1971)28:5<1142::AID-CNCR2820280509>3.0.CO;2-A
IF: 6.9209
Cancer
Abstract:Bleomycin is an antitumor antibiotic produced by Streptomyces verticillus. Seventy‐five patients with various neoplasms were studied using this drug. Fourteen out of 20 patients with epidermoid carcinoma of the head and neck region, 5 out of 14 cases of lymphoma including Hodgkin's disease, 3 out of 6 patients with testicular tumors, and one patient with lymphangiosarcoma of the arm showed evidence of objective regression. Common side effects encountered were hyperthermic reactions, gastrointestinal disturbances, hyperkeratosis and vesiculation of fingers, alopecia, and stomatitis. Pulmonary fibrosis is a rare but serious complication. One patient in this series died of this complication. There was no evidence of bone marrow, liver, or renal toxicity. Bleomycin promises to be a useful therapeutic agent and merits further study.
What problem does this paper attempt to address?